ATE331026T1 - Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel - Google Patents

Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel

Info

Publication number: ATE331026T1
Authority: AT; Austria
Prior art keywords: pct; gene product; hiv; antigenic marker; marker
Prior art date: 1994-08-15

Application number

AT95927611T

Other languages

English (en)

Inventor

Benjamin Rovinski

Shi-Xian Cao

Fei-Long Yao

Roy Persson

Michel H Klein

Original Assignee

Sanofi Pasteur Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-15

Filing date

1995-08-15

Publication date

2006-07-15

1995-08-15 Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd

2006-07-15 Application granted granted Critical

2006-07-15 Publication of ATE331026T1 publication Critical patent/ATE331026T1/de

Links

208000015181 infectious disease Diseases 0.000 title abstract 4
239000002245 particle Substances 0.000 title abstract 3
239000003550 marker Substances 0.000 abstract 6
230000000890 antigenic effect Effects 0.000 abstract 5
101710177291 Gag polyprotein Proteins 0.000 abstract 2
241000723873 Tobacco mosaic virus Species 0.000 abstract 2
230000002458 infectious effect Effects 0.000 abstract 2
101710132601 Capsid protein Proteins 0.000 abstract 1
101710094648 Coat protein Proteins 0.000 abstract 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract 1
208000031886 HIV Infections Diseases 0.000 abstract 1
208000037357 HIV infectious disease Diseases 0.000 abstract 1
101710125418 Major capsid protein Proteins 0.000 abstract 1
101710141454 Nucleoprotein Proteins 0.000 abstract 1
101710083689 Probable capsid protein Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
230000036436 anti-hiv Effects 0.000 abstract 1
108700004025 env Genes Proteins 0.000 abstract 1
101150030339 env gene Proteins 0.000 abstract 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
238000003780 insertion Methods 0.000 abstract 1
230000037431 insertion Effects 0.000 abstract 1
108010089520 pol Gene Products Proteins 0.000 abstract 1
230000003362 replicative effect Effects 0.000 abstract 1
230000001177 retroviral effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Food Science & Technology (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)

AT95927611T 1994-08-15 1995-08-15 Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel ATE331026T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/290,105 US5955342A (en)	1994-08-15	1994-08-15	Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region

Publications (1)

Publication Number	Publication Date
ATE331026T1 true ATE331026T1 (de)	2006-07-15

Family

ID=23114550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95927611T ATE331026T1 (de)	1994-08-15	1995-08-15	Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel

Country Status (12)

Country	Link
US (5)	US5955342A (de)
EP (1)	EP0778888B1 (de)
JP (2)	JP3871708B2 (de)
AT (1)	ATE331026T1 (de)
AU (1)	AU704309B2 (de)
CA (1)	CA2197446A1 (de)
DE (1)	DE69535075T2 (de)
DK (1)	DK0778888T3 (de)
ES (1)	ES2268693T3 (de)
MX (1)	MX9701149A (de)
PT (1)	PT778888E (de)
WO (1)	WO1996005292A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6080408A (en)	1994-08-22	2000-06-27	Connaught Laboratories Limited	Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU702802B2 (en)	1994-10-18	1999-03-04	Scottish Crop Research Institute	Method of producing a chimeric protein
WO1996030523A2 (en) *	1995-03-31	1996-10-03	Hans Wolf	Antigen presentation system based on retrovirus-like particles
GB9607899D0 (en) *	1996-04-17	1996-06-19	Scottish Crop Research Inst	Virus-like particle
US6602505B2 (en)	1998-04-30	2003-08-05	University Of Southern California	Viral chimeras comprised of CAEV and HIV-1 genetic elements
CA2331599C (en)	1998-05-12	2005-11-29	Genecure Llc	Replication defective hiv vaccine
AU2596600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Modified hiv env polypeptides
WO2000039304A2 (en)	1998-12-31	2000-07-06	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1980617A1 (de) *	1998-12-31	2008-10-15	Novartis Vaccines and Diagnostics, Inc.	Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1221968B1 (de) *	1999-10-13	2010-01-13	Novartis Vaccines and Diagnostics, Inc.	Verfahren zur erhaltung zellimmuneantworten gegen proteinen
WO2001092470A2 (en)	2000-03-02	2001-12-06	Emory University	Dna expression vectors and methods of use
US8623379B2 (en) *	2000-03-02	2014-01-07	Emory University	Compositions and methods for generating an immune response
US20040105871A1 (en) *	2000-03-02	2004-06-03	Robinson Harriet L.	Compositions and methods for generating an immune response
WO2002000169A2 (en) *	2000-06-26	2002-01-03	The United States Of America, As Represented By The Secretary Of Agriculture	Production of vaccines using transgenic plants
US6461616B1 (en) *	2000-09-09	2002-10-08	Akzo Nobel Nv	EIAV p26 deletion vaccine and diagnostic
WO2002020049A2 (en) *	2000-09-09	2002-03-14	Akzo Nobel N.V.	Eiav chimeric vaccine and diagnostic
US7122180B2 (en) *	2000-10-23	2006-10-17	Children's Medical Center Corporation	DNA vectors containing mutated HIV proviruses
EP1201750A1 (de) *	2000-10-26	2002-05-02	Genopoietic	Synthetische Viren und ihre Verwendungen
PT1372710E (pt) *	2001-03-08	2009-12-21	Us Gov Health & Human Serv	Vam modificado que expressa os genes gag e pol do envelope de vih
US20030198621A1 (en) *	2001-07-05	2003-10-23	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CA2452015C (en)	2001-07-05	2012-07-03	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1427806A4 (de) *	2001-08-31	2006-04-26	Chiron Corp	Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon
US20030170614A1 (en) *	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2003077838A2 (en) *	2002-03-05	2003-09-25	National Institutes Of Health Office Of Technology Transfer	Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
AU2003278496A1 (en) *	2002-11-14	2004-06-03	Pfizer Products Inc.	Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
EP2025762A3 (de)	2006-01-17	2009-09-30	Health Research Inc.	Heteroduplex-Trackingassay
CA2688548A1 (en) *	2007-05-02	2009-01-15	Emory University	Enhancement of glycoprotein incorporation into virus-like particles
WO2011119920A2 (en)	2010-03-25	2011-09-29	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
SMT201800284T1 (it)	2011-06-10	2018-07-17	Univ Oregon Health & Science	Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (de)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de)	2011-10-27	2013-05-01	Christopher L. Parks	Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5352449A (en) *	1986-05-30	1994-10-04	Cambridge Biotech Corporation	Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
GB8923123D0 (en) *	1989-10-13	1989-11-29	Connaught Lab	A vaccine for human immunodeficiency virus
JPH05501201A (ja) *	1989-10-16	1993-03-11	ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ	非感染性ｈｉｖ―１粒子およびそれらの使用
WO1991007425A1 (en) *	1989-11-20	1991-05-30	Oncogen Limited Partnership	Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) *	1990-06-19	1991-12-26	Applied Biotechnology, Incorporated	Self assembled, defective, nonself-propagating viral particles
AU678152B2 (en) *	1992-03-27	1997-05-22	Whitehead Institute For Biomedical Research	Non-infectious HIV particles and uses therefor
AU4685293A (en) *	1992-07-20	1994-02-14	Immune Response Corporation, The	Prophylactic and therapeutic control of retroviral infections
GB9412844D0 (en) *	1994-06-27	1994-08-17	Medical Res Council	Improvements in or relating to therapeutic methods

1994
- 1994-08-15 US US08/290,105 patent/US5955342A/en not_active Expired - Lifetime
1995
- 1995-06-06 US US08/470,419 patent/US5866320A/en not_active Expired - Lifetime
- 1995-08-15 ES ES95927611T patent/ES2268693T3/es not_active Expired - Lifetime
- 1995-08-15 DK DK95927611T patent/DK0778888T3/da active
- 1995-08-15 AU AU31599/95A patent/AU704309B2/en not_active Ceased
- 1995-08-15 CA CA002197446A patent/CA2197446A1/en not_active Abandoned
- 1995-08-15 EP EP95927611A patent/EP0778888B1/de not_active Expired - Lifetime
- 1995-08-15 AT AT95927611T patent/ATE331026T1/de active
- 1995-08-15 JP JP50688396A patent/JP3871708B2/ja not_active Expired - Fee Related
- 1995-08-15 WO PCT/CA1995/000483 patent/WO1996005292A1/en not_active Ceased
- 1995-08-15 MX MX9701149A patent/MX9701149A/es active IP Right Grant
- 1995-08-15 US US08/776,949 patent/US6025125A/en not_active Expired - Lifetime
- 1995-08-15 DE DE69535075T patent/DE69535075T2/de not_active Expired - Lifetime
- 1995-08-15 PT PT95927611T patent/PT778888E/pt unknown
1996
- 1996-12-06 US US08/761,209 patent/US5889176A/en not_active Expired - Lifetime
- 1996-12-06 US US08/761,828 patent/US5879925A/en not_active Expired - Lifetime
2005
- 2005-07-21 JP JP2005211860A patent/JP2006020635A/ja active Pending

Also Published As

Publication number	Publication date
EP0778888B1 (de)	2006-06-21
DE69535075D1 (de)	2006-08-03
AU3159995A (en)	1996-03-07
DE69535075T2 (de)	2007-01-04
DK0778888T3 (da)	2006-10-23
ES2268693T3 (es)	2007-03-16
AU704309B2 (en)	1999-04-22
WO1996005292A1 (en)	1996-02-22
PT778888E (pt)	2006-11-30
EP0778888A1 (de)	1997-06-18
US5955342A (en)	1999-09-21
JP2006020635A (ja)	2006-01-26
US5866320A (en)	1999-02-02
JP3871708B2 (ja)	2007-01-24
US5879925A (en)	1999-03-09
JPH10503933A (ja)	1998-04-14
MX9701149A (es)	1997-05-31
CA2197446A1 (en)	1996-02-22
US6025125A (en)	2000-02-15
US5889176A (en)	1999-03-30

Legal Events

Date

Code

Title

Description

2007-04-15

UEP

Publication of translation of european patent specification

Ref document number: 0778888

Country of ref document: EP

Publication	Publication Date	Title
DE69535075D1 (de)	2006-08-03	Antigen-markierte nicht-infektiöse retrovirus-ähnlige partikel
Osterhaus et al.	1985	Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
Nara et al.	1988	Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies
Bonsignori et al.	2009	HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
DE69535757D1 (de)	2008-07-03	Rekombinanter immunschwächepoxvirus
MY136081A (en)	2008-08-29	Modified hiv - 1gag p17 peptide and immunogenic composition
SE8701413L (sv)	1987-10-05	Expression och rening av en htlv-iii gag/env-gen protein
ATE154610T1 (de)	1997-07-15	Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
ID30497A (id)	2001-12-13	Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
ATE153071T1 (de)	1997-05-15	Neue proteinhaltige partikeln
Alves et al.	2017	Evaluation of Plasmodium vivax cell-traversal protein for ookinetes and sporozoites as a preerythrocytic P. vivax vaccine
ATE36956T1 (de)	1988-09-15	Verfahren zu herstellung von lebenden, adjuvierten impfstoffen und so erhaltende lebende, adjuvierte impfstoffe.
ES2066887T3 (es)	1995-03-16	Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
EP0433242A1 (de)	1991-06-19	Impfstoffe und Verfahren zu deren Herstellung
Verrier et al.	2000	A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
DK0880360T3 (da)	2003-01-27	Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
Haffar et al.	1991	HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles
EA200300335A1 (ru)	2003-08-28	Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Merza et al.	1989	Bovine leukaemia virus ISCOMs: biochemical characterization
IL86675A (en)	1993-04-04	Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same
Decroix et al.	2002	Mucosal Immunity Induced by Intramuscular Administration of Free Peptides In‐Line with PADRE: IgA Antibodies to the ELDKWA Epitope of HIV gp41
Cole et al.	1997	A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys
Pincus et al.	1994	Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
KR960705919A (ko)	1996-11-08	제릴-린(jeryl-lynn) 바이러스 균주를 함유하는 유행성 귀밑샘염에 대한 백신(vaccine against mumps containing a jeryl-lynn virus strain)
Höglund et al.	1990	Characterization of immunostimulating complexes (ISCOMs) of HIV-1